Composition: Each vial contains Ifosfamide USP 2 gm Injection.
Indications: Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis hemorrhagic cystitis.
Dosage and Administration: Ifosfamide should be administrated intravenously at a dose of 1.2 g/m2 per day for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from hematologic toxicity (Platelets >_ 100,000/mL, WBC >_ 4,000/mL). In order to prevent bladder toxicity, ifosfamide should be given with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day. A protector, such as Mesna (Mes-D), should also be used to prevent hemorrhagic cystitis. Ifosfamide should be administrated as a slow intravenous infusion lasting a minimum of 30 minutes. Or, as directed by the registered physician.
Use in Pregnancy and Lactation: Pregnancy Category D. Ifosfamide can cause fetal harm when administered to a pregnant woman. Fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. Ifosfamide is excreted in breast milk. Because of the potential for serious adverse events and the tumorigenicity shown for ifosfamide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Packaging: Each box contains one vial of Ifosfamide 2 gm Lyophilized Powder.